Related Experiment Video
Updated: Apr 30, 2026

Oral Health Assessment by Lay Personnel for Older Adults
Published on: February 2, 2020
[Methodology for analysing quality-of-life data in the benefit assessment of pharmaceuticals]
1Pfizer Deutschland GmbH, Berlin.
Abstract:
Early benefit assessment aims to prove a benefit of a new pharmaceutical over the appropriate comparator based on patient-relevant endpoints. In addition to mortality and morbidity, quality of life is a patient-relevant endpoint. Thus, phase III clinical trials are the basis of evidence. But HTA and health authorities attach different importance to quality of life. Using the example of oncology, the challenges with study design and analysis will be discussed. A particular challenge to the analysis of quality-of-life data is varying observation times in treatment arms with different effectiveness. Based on the example of Crizotinib possible solutions will be presented.
Related Concept Videos
Measurement of Bioavailability: Pharmacodynamic Methods
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence Data: Statistical Interpretation
Analysis of Population Pharmacokinetic Data
Bioavailability Study Design: Healthy Subjects Versus Patients
Measurement of Bioavailability: Pharmacokinetic Methods
